NCT01967134View on ClinicalTrials.gov

Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

June 30, 2013

Conditions
Latent TuberculosisLatent Tuberculosis Bacteriology and Histology Unknown
Interventions
BIOLOGICAL

H56:IC31

H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.

Trial Locations (1)

6850

SATVI Project Office, Brewelskloof Hospital, Worcester

Sponsors

Lead Sponsor

Aeras
All Listed Sponsors
collaborator

Statens Serum Institut

OTHER

lead

Aeras

OTHER

NCT01967134 - Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis | Biotech Hunter | Biotech Hunter